<?xml version="1.0" encoding="UTF-8"?>

<?xml-stylesheet type="text/xsl" href="/static/oaitohtml.xsl"?>

<!--
<?xml-stylesheet type="text/xsl" href="/oaitohtml.xsl"?>
-->

<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <responseDate>2026-10-14T23:46:50Z</responseDate>
    <request verb="GetRecord" metadataPrefix="oai_dc" identifier="10.57760/sciencedb.0125w" >https://www.scidb.cn/oai</request>
<GetRecord>
    <record>
    <header >
    <identifier>10.57760/sciencedb.0125w</identifier>
    <datestamp>2026-09-10T14:05:25Z</datestamp>
</header>
    <metadata>
        
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:date>2026-09-10</dc:date>
  <dc:title>Blood components of JSXZD-FR</dc:title>
  <dc:identifier>doi:10.57760/sciencedb.0125w</dc:identifier>
  <dc:language>en</dc:language>
  <dc:description>This dataset contains the identified blood-absorbed components of the fermented preparation of Jishen Xingzhi Decoction (JSXZD-FR), based on UPLC-MS/MS analysis of drug-containing serum from SD rats. SD rats were randomly divided into a blank group, a JSXZD-R group, and a JSXZD-FR group, with three rats in each group. Rats in the JSXZD-FR group were administered JSXZD-FR at a dose of 0.93 g/(kg&amp;middot;d) by gavage at the same time each day, 1 mL per rat, once daily for three consecutive days. Before the final administration, the rats were fasted, and blood samples were collected 1 h after gavage. The samples were analyzed using a UPLC-MS/MS platform. The chromatographic conditions included an injection volume of 4 &amp;mu;L, a flow rate of 0.40 mL/min, and a column temperature of 40 &amp;deg;C, with ultrapure water containing 0.10% formic acid as mobile phase A and acetonitrile as mobile phase B. Electrospray ionization (ESI) was used for mass spectrometric detection, and data-dependent acquisition was performed in both positive- and negative-ion modes. Raw mass spectrometry data were processed using XCMS for peak extraction, peak alignment, and retention-time correction. Metabolites were identified by matching against an in-house database, public databases, prediction databases, and the metDNA method. Compounds with an overall identification score greater than 0.50 and a coefficient of variation (CV) below 0.50 in QC samples were retained. Data from positive- and negative-ion modes were subsequently merged, and records with higher identification confidence and lower CV values were preferentially retained.Supplementary Table 2 contains 30 records of blood-absorbed components identified in the JSXZD-FR group, with each row representing one screened and curated compound record. The table mainly includes Molecular Formula, Compound, retention time (tR, min), molecular weight, Biological Function, and Classification. The tR value represents chromatographic retention time and is expressed in minutes. Molecular formula and compound name describe the chemical identity of each identified compound; Biological Function provides functional annotation information; and Classification indicates the corresponding chemical category. The identified compounds include amino acids and their derivatives, organic acids, flavonoids, terpenoids, alkaloids, lipids, alcohols, and amines.This dataset consists of laboratory-based mass spectrometric detection and compound-identification data and therefore does not involve geographic coordinates, spatial coverage, or spatial resolution. It is also not a continuous time-series dataset and thus has no temporal resolution. The main time-related information concerns three consecutive days of administration and blood collection 1 h after the final gavage. Most fields are complete; however, the Biological Function field is recorded as &amp;ldquo;/&amp;rdquo; for (3beta,5alpha,6beta,9alpha,22E,24R)-23-Methylergosta-7,22-diene-3,5,6,9-tetrol and N-[2-(5-Hydroxy-1H-indol-3-yl)ethyl]octadecanamide, indicating that no corresponding functional annotation was provided. No separate error range or confidence interval is reported for individual compound measurements. Data quality was controlled through QC-based CV filtering, integration of positive- and negative-ion mode data, and metabolite identification score filtering. Compound identification may still be affected by chromatographic peak extraction and alignment, retention-time correction, mass spectrometric signal quality, database matching, and metabolite annotation. The dataset is provided in .xlsx format and can be accessed using common spreadsheet software such as Microsoft Excel or WPS Office.</dc:description>
  <dc:subject>JSXZD-FR; blood components; UPLC-MS/MS</dc:subject>
  <dc:creator>siyaoliang</dc:creator>
  <dc:creator>changwuyue</dc:creator>
  <dc:rights>PUBLIC</dc:rights>
  <dc:rights>https://creativecommons.org/licenses/by-sa/4.0/</dc:rights>
  <dc:type>dataset</dc:type>
  <dc:publisher>Science Data Bank</dc:publisher>
</oai_dc:dc>

    </metadata>
</record>
</GetRecord>
</OAI-PMH>